Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper

MLA

José Bravo Marques, et al. “Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.” Drug Safety, vol. 44, June 2021, pp. 825–34. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........93e6d37fbb74c873ac16ed51f006e00b&authtype=sso&custid=ns315887.

APA

José Bravo Marques, Venceslau Hespanhol, Carlos Aguiar, Tiago Reis Marques, & Fernando Barata. (2021). Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper. Drug Safety, 44, 825–834.

Chicago

José Bravo Marques, Venceslau Hespanhol, Carlos Aguiar, Tiago Reis Marques, and Fernando Barata. 2021. “Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.” Drug Safety 44 (June): 825–34. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........93e6d37fbb74c873ac16ed51f006e00b&authtype=sso&custid=ns315887.